Scientific Online Resource System

Scripta Scientifica Medica

Vitamin D status in patients with psoriasis

Stoyan Ivanov Pavlov, Irina Ivanova Ivanova, Daniela Gerova

Abstract

Introduction: Vitamin D may act as immune modulator in psoriasis and be related with disease characteristics. Our study aimed to evaluate the vitamin D status in patients admitted for diagnostics or exacerbation of psoriasis.

Material and methods: 92 patients (50 male, 42 female, mean age 55 years) were included in analysis. Disease severity was assessed by Psoriasis Area and Severity Index (PASI). Type of disease was classified according to age at presentation as early (up to 40 years) and late (above 40 years). Serum levels of 25-hydroxyvitamin D, 25(OH)D, were tested with immune fluorescent method (ADVIA Centaur Vitamin D Total, Siemens).

Results: The mean level of 25(OH)D in psoriatic patients was 12.07 ng/ml (30.18 nmol/l), found at low limit of insufficiency; related 95% CI range was 10.55 - 13.60 ng/ml (26.38 - 33.99 nmol/l). A total of 45 of 92 patients (48.9%) had vitamin D insufficiency (defined as 25 (OH) D level of 10 to 30 ng/ml), 44 patients (47.82%) had deficiency (< 10 ng/ml) and only in 3 patients 25(OH)D was assessed at level of sufficiency. Vitamin D level correlate with PASI (r=-0.508), but does not correlate with C-reactive protein. No significant difference in vitamin D status was observed in patients with obesity and early type 1 psoriasis.

Conclusion: High prevalence (47.83%) of vitamin D deficiency in patients with moderate and severe psoriasis suspects the role of vitamin D in pathogenesis of disease exacerbation. Vitamin D therapeutic supplementation needs to be clarified by further studies.


Keywords

psoriasis; vitamin D; vitamin D deficiency

Full Text


References

Bibliography

Iskandar IYK, Ashcroft DM, Warren RB, et al. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. Br. J. Dermatol. 2015;173:510-518.

Tsoi LC, Spain SL, Knight J, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat. Genet. 2012;44:1341-1348.

Malkic Salihbegovic E, Hadzigrahic N, Cickusic AJ. Psoriasis and Metabolic Syndrome. Med. Arch. 2015;69:85-87.

Finamor DC, Sinigaglia-Coimbra R, Neves LCM, et al. A pilot study assessing the effect of prolonged administration of high daily doses of vitamin D on the clinical course of vitiligo and psoriasis. Dermatoendocrinol. 2013;5:222-234.

Hayes CE, Hubler SL, Moore JR, et al. Vitamin D Actions on CD4(+) T Cells in Autoimmune Disease. Front. Immunol. 2015;6:100.

Yap KS, Northcott M, Hoi AB-Y, et al. Association of low vitamin D with high disease activity in an Australian systemic lupus erythematosus cohort. Lupus Sci. Med. 2015;2:e64.

Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J. Am. Acad. Dermatol. 1985;13:450-456.

Krasowski MD. Pathology consultation on vitamin D testing. Am. J. Clin. Pathol. 2011;136:507-514.

Nair R, Maseeh A. Vitamin D: The `sunshine` vitamin. J. Pharmacol. Pharmacother. 2012;3:118-126.

Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol. Med. 2002;8:174-179.

Szodoray P, Nakken B, Gaal J, et al. The complex role of vitamin D in autoimmune diseases. Scand. J. Immunol. 2008;68:261-269.

Hong Q, Xu J, Xu S, et al. Associations between serum 25-hydroxyvitamin D and disease activity, inflammatory cytokines and bone loss in patients with rheumatoid arthritis. Rheumatology (Oxford). 2014;53:1994-2001.

Balato A, Schiattarella M, Lembo S, et al. Interleukin-1 family members are enhanced in psoriasis and suppressed by vitamin D and retinoic acid. Arch. Dermatol. Res. 2013;305:255-262.

Fu LW, Vender R. Systemic role for vitamin d in the treatment of psoriasis and metabolic syndrome. Dermatol. Res. Pract. 2011;2011:276-279.

Creamer D, Sullivan D, Bicknell R, et al. Angiogenesis in psoriasis. Angiogenesis 2002;5:231-236.

Wilson PB. Serum 25-hydroxyvitamin D status in individuals with psoriasis in the general population. Endocrine 2013;44:537-539.

Orgaz-Molina J, Buendia-Eisman A, Arrabal-Polo MA, et al. Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: a case-control study. J. Am. Acad. Dermatol. 2012;67:931-938.

Gisondi P, Rossini M, Cesare A Di, et al. Vitamin D status in patients with chronic plaque psoriasis. Br. J. Dermatol. 2012;166:505-510.

Ricceri F, Pescitelli L, Tripo L, et al. Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis. J. Am. Acad. Dermatol. 2013;68:511-512.

Borissova AM, Shinkov A, Vlahov J, et al. Frequency of deficiency, insufficiency and sufficiency of vitamin D in Bulgarian population (≥ 20-80 years old). Endokrinologya 2012;17:122-134.

Perez A, Raab R, Chen TC, et al. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br. J. Dermatol. 1996;134:1070-1078.




DOI: http://dx.doi.org/10.14748/ssm.v1i1.1495

Refbacks

About The Authors

Stoyan Ivanov Pavlov
Clinic of Dermatology and Venereology, Medical University of Varna
Bulgaria

Irina Ivanova Ivanova
Clinic of Gastroenterology, Department of Internal Medicine, Medical University of Varna

Daniela Gerova
Clinical Laboratory, Medical University of Varna

Font Size


|